New tool could spot tough pneumonia early
NCT ID NCT07425561
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study created and tested a risk score called RESPIRE to predict whether a patient's pneumonia is caused by multidrug-resistant bacteria. Researchers looked at data from 300 adults with community-acquired pneumonia in the emergency department. The goal is to help doctors quickly identify high-risk patients, but the score is not yet ready for routine use.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could give doctors a simple tool to quickly identify pneumonia patients at risk for drug-resistant infections, helping guide early treatment decisions.
- What could go wrong
- This is an observational study, not a treatment trial. The score needs further testing in other hospitals and may not work as well in different populations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COMMUNITY ACQUIRED PNEUMONIA, SEVERE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Careggi University Hospital
Florence, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- AI could outsmart bacteria: a smarter way to choose antibiotics?
- Breathing technique may outperform spirometry for smog pneumonia recovery
- A gentle touch against coughs and colds: could manual therapy shorten respiratory illness?
- Can a smart oxygen device shorten hospital stays for pneumonia?
- Could everyday supplements shield your lungs?
- Can a simple inhaled combo keep pneumonia patients off ventilators?